Drugs.com Clinical Trial ResultsOriginal article
JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis
Data ReadoutpositivebrepocitinibPositive
AI Analysis
Summary
Priovant Therapeutics announced publication of skin-specific outcomes from the Phase 3 VALOR trial of brepocitinib, a first-in-class oral TYK2 and JAK1 inhibitor, in JAMA Dermatology for the treatment of dermatomyositis.
Clinical Trial Data
Phase
Phase 3
Outcome Details
Skin-specific outcomes from Phase 3 VALOR trial published in JAMA Dermatology
Importance:6/10
Sentiment:
0.70
Phase 3dermatologyskin outcomespublicationTYK2JAK1
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on August 26, 2026 11:08 PM